KRAS drug developers offer early data on new classes of small molecules
Saturday, November 30, 2019 - 12:25
in Health & Medicine
Mirati unveils the first clinical data on its KRAS G12C inhibitor, while Amgen and Boehringer provide clues on how to expand the number of patients benefiting from KRAS-targeted drugs